- Does Prostate Cancer belong to Family Inherited Tumors?
- The most dangerous breast cancer: 3-year overall survival rate of combined immunotherapy before surgery is 95.2%
- Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline
- The most expensive drug ever: FDA approves gene therapy priced at $2.8 million
- WHO renames monkeypox virus to avoid negative impact on monkeys
- New hope for Paralysis: A man wears brain-computer interface for seven years
IIs CAR or TCR immunotherapy better in cancer treatment?
- 14 hospitals in Japan issued a “blood warning”
- Oxford study finds increased risks of dementia two years after contracting COVID-19
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Is CAR or TCR immunotherapy better in cancer treatment?
One of the most powerful treatment strategies in immunotherapy is adoptive cell transfer (ACT) (Figure 1). Chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) are the most recently used T cell receptors for therapeutic T cell immunotherapy (11, 12).
TCR engineered T cells express tumor antigen-specific receptors with α and β chains, which are produced by high-quality and high-affinity antigen-specific T cell clones. They are used to develop antigen-specific immunotherapy (13).
The high affinity and cell affinity of TCR-T cells determine the specific binding of several cell proteins, which means that TCR plays a key role in activating T cell affinity.
Compared with low-affinity TCR, which reduces the efficiency of TCR treatment, high-affinity TCR (affinity ≥ 2.5 nM) is specific and sensitive to target cell surface human leukocyte antigen (HLA) (14).
TCR molecules belong to the immunoglobulin superfamily and consist of two covalently bound polymorphic subunits. Each subunit has antigen specificity and is associated with at least four different types of signal transduction chains.
Figure 1 Adoptive T cell therapy. In adoptive cell therapy (ACT), cells are collected from cancer tissues/T cells, then separated from other cells, genetically manipulated through engineered TCR or CAR, co-cultured and proliferated, and finally returned to the circulation.
In order to activate T lymphocytes, there must be an interaction between TCR and the major histocompatibility complex (MHC) (Figure 2). The strength of the interaction between TCRs and pMHC (peptide-MHC) determines the fate of immature thymocytes, which is very important for the survival of naive T cells.
Therefore, TCR-T immunotherapy technology activates the host’s immune system through effective interaction with MHC, especially class II molecules; the latter is specifically recognized by TCR-T cells and CAR-T cells (15).
TCR-T cells penetrate the tumor, but CAR-T cells are mainly distributed around the tumor to contact surface antigens. This makes TCR-T cells more effective in cancer treatment (16).
Figure 2 The interaction between MHC peptides and T cells. Cytotoxic T cells (CD8+) recognize MHC-I, CD3 coupled TCRs, and these TCRs activate T cell signaling cascades, including calcium-dependent and protein kinase C signaling pathways (PKC). Calcium is a nuclear factor that activates activated T cells (NFAT), leading to the expression and secretion of interleukin (IL)-2, and PKC activation leads to the regulation and regulation of ILs, including IL-2, migration necessary for the production and secretion of T cells, T cell proliferation, autoimmunity, and transplant rejection. CD4+ T cells can shut down the immune system by promoting regulatory T cells (Treg). In order to activate T cell proliferation, TCR also triggers p38MAPK and PI3K/Akt pathways. Once CD4 or CD8 activates TCR, it activates lymphocyte-specific protein tyrosine kinase (Lck), which triggers the phosphorylation of the CD3 ζ chain.
In ACT, TCR and CAR therapies, modified T cells have been successfully used as paradigm-shifting clinical immunotherapy for the treatment of solid tumors (17) (Figure 3). CAR T cells are designed to transfer any specificity to immune effector cells, such as T cells, which specifically eliminate antigen-carrying tumor cells (17). CAR has scFv derived from antibody, CD3ζ, and transmembrane domain (the so-called first-generation CAR) (18). In this way, the engineered CAR can recognize specific tumor-associated antigens (19). Therefore, CAR can bind to unprocessed tumor surface antigens without MHC processing (20), while TCR binds to tumor cells embedded in MHC and surface antigen peptides (Table 1) (21).
Generally, CAR scFv domains are used to bind to cell surface antigens (22). The scFv fragment can guide the constitutive activation and proliferation of T cells through an antigen-dependent mechanism; however, some scFv may guide T cells into an antigen-independent mechanism, leading to treatment failure (23).
Figure 3 Comparison of TCR, CAR and transgenic T cells in immunotherapy. The cancer-targeted receptors TCR and CAR are introduced into activated T cells, enabling them to resist specific types of cancer. The ζ subunit of CD3 on the surface of T cells is essential for triggering the signal cascade of T cells. Unlike TCR, which needs to be activated by endogenous CD3, CAR is a hybrid receptor made from a single-chain variable fragment (scFv) linked to the CD3 ζ subunit. Both imported and endogenous TCR can recognize HLA peptides on cancer cells. In contrast, CAR does not directly recognize HLA, which triggers the T cell signaling cascade in a way that is independent of TCR.
In addition, the first generation of CARs T cells showed limited expansion and relatively short persistence, which failed to stimulate strong anti-tumor activity in clinical studies (24, 25).
The clinical activity of “second-generation” CARs can be induced by the insertion of the CD3ζ domain, namely the costimulatory receptors CD28 (28ζ), 4-1BB/CD137 (BBζ) and OX40 (OX40ζ) CAR (26-28).
CD28 or CD137/4-1BB is added to the CD3ζ domain of CAR-T cells, which then promotes a more powerful and durable T cell response (29, 30). In addition, these second-generation CARs targeting CD19 antigen (CD19-specific scFv) are highly active against B-cell malignancies and have good clinical benefits (31, 32).
In order to overcome the limitations of each individual costimulatory domain, the third generation of CARs is proposed to combine two costimulatory signals (CD28 and 4-1BB) at the same time, which has better scalability and longer than the second generation. Persistence (33).
In contrast, TCR is an α/β heterodimer that binds to MHC binding antigens (Figure 3). As mentioned above, compared with TCR, CAR recognizes tumor antigens that cause T cell activation and has different functions. CAR-T cell therapy has certain disadvantages when targeting tumor-specific antigens, such as extra-tumor toxicity (34).
Compared with CAR, TCR has several structural advantages in T cell-based therapy, because their receptor structure has more subunits (ten subunits to one subunit) and larger immune receptors. Amino acid activation motifs (ITAM) (ten to three), less dependent on antigen (1 to 100), and more costimulatory receptors (CD3, CD4, CD28, etc.) (20).
TCRs with a low MHC interaction affinity range (104-106M-1) have been suggested for effective T cell stimulation (35). In contrast, CARs have a higher affinity range (106-109M-1) and dissociation rate to recognize cell surface antigens (20). In order to maintain high antigen sensitivity and recognize pMHC, the use of monomeric TCR-CD3 complexes has been recommended (21).
In contrast, CAR-mediated cell sensitivity depends on a higher density of cell surface antigens (36). In addition, the T cell/antigen interaction is initiated in the immune synapse (IS) structure, where TCR presents a circular area with peripheral LFA-1 adhesion, while CAR shows diffuse LFA-1 distribution without a circular area (37).
Therefore, TCR-IS initiates a slower but longer lasting signal than CAR-IS. At the same time, CAR-T cells show faster killing function and transfer to the next tumor target (continuous killing), which is in sharp contrast with the prolonged signal and longer killing time of TCR-T cells.
Clinical trials involving TCR and CAR therapies may inhibit tumor progression. CARs cannot effectively inhibit the malignant cells of certain solid tumors.
This is due to the existence of various types of antigens, their expression levels, immunosuppressive environment and the construction of CARs.
However, TCR-T cell transfer therapy has effectively treated some solid tumors and hematomas (37).
Front. Immunol., 30 March 2021 | https://doi.org/10.3389/fimmu.2021.658753
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Prosand Cons
Is CAR or TCR immunotherapy better in cancer treatment?
(source:internet, reference only)